Atlas Trials

Canakinumab in Patients With Active Hyper-IgD Syndrome

Clinical trial NCT01303380 · COMPLETED

Trial details

NCT number
NCT01303380
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Mevalonate Kinase Deficiency
Start date
2011-03-01
Primary completion
2014-07-01
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.